7 results about "IGFBP7" patented technology

The invention relates to application of IGFBP7 in clinical diagnosis of colorectal cancer and application of IGFBP7 as a drug target. The research shows that the expression quantity of IGFBP7 secreted by tumor endothelial cells is continuously reduced in the colorectal tumor formation process related to inflammation. Functional analysis proves that the endothelial-derived IGFBP7 is secreted into a tumor microenvironment and plays a role in resisting angiogenesis. In addition, the CRC cells can actively ingest the vesicles containing the IGFBP7. The IGFBP7 reduces the activity of a TGF-beta1 signal channel by inhibiting the expression of EGR1, thereby inhibiting the proliferation and migration of tumor cells. What is worthy of attention is that VAPA (Vesicle-associated Membrane Protein Associated Protein A) is identified to be a key factor for mediating IGFBP7 vesicles to be transferred to lysosome, and VAPA promotes the degradation of IGFBP7, so that the cancer suppression function of the IGFBP7 is weakened. The endothelial cell-derived IGFBP7 inhibits the progress of CRC (cyclic redundancy check) through an EGR1 / TGF-beta 1 pathway, and VAPA-mediated lysosome degradation limits the cancer inhibition effect of the endothelial cell-derived IGFBP7. The discovery emphasizes that the endothelial cell-derived IGFBP7 is a promising therapeutic target in the field of colorectal cancer.

The application belongs to the technical field of biotechnology, and particularly relates to a pharmaceutical composition containing exosomes and application thereof. The pharmaceutical composition containing exosomes comprises stem cell exosomes, recombinant IGFBP7 protein and baeckea fruitin B; the amino acid sequence of the recombinant IGFBP7 protein is shown as SEQ ID NO:1. Test results show that the combination of umbilical cord mesenchymal stem cell exosomes, baeckea fruitin B and recombinant IGFBP7 protein can stimulate hair follicle stem cells, prolong the initial stage of hair growth of hair follicles, and thus effectively improve the hair loss of patients.

The present invention relates to an antibody or antigen binding fragment thereof that binds specifically to IGFBP7 and has pro-survival activity, decreases stress-mediated senescence / inflammation and pro-fibrotic tissue injury. In particular, the invention relates to antibodies or antigen binding fragments thereof that bind with high affinity and specificity to human IGFBP7 and / or to at least one of its receptors.

The invention relates to the technical field of pharmaceutical biology, aims to solve the problem of lack of specific detoxification drugs for treating glyphosate poisoning clinically, and particularly provides application of chlorogenic acid in preparation of drugs for treating glyphosate-induced renal toxicity diseases. The drug mechanism of the chlorogenic acid is as follows: glyphosate-induced renal toxicity is antagonized through targeted renal injury biomarkers, wherein the renal injury biomarkers comprise TIM-1, TIMP-2, IGFBP7 and LCN2. The invention also provides a preparation for preventing and / or relieving and / or treating glyphosate-induced renal toxicity diseases, wherein the preparation contains chlorogenic acid. The preparation can be a medicine, a pharmaceutical composition, a health care product, a food or an additive. The medicine prepared by the invention can be used for remarkably reducing the expression levels of TIM-1, TIMP-2, IGFBP7 and LCN2 of the GLY-induced renal injury. In addition, oxidative stress (LCN2), cell cycle arrest (TIMP-2 / IGFBP7) and inflammatory reaction (TIM-1) can be synchronously and accurately inhibited, and the curative effect is superior to that of a current single-channel medicine.

The invention belongs to the technical field of medical biology, and particularly relates to application of IGFBP7 in preparation of a medicine for treating gastric adenocarcinoma. IGFBP7 closely related to gastric adenocarcinoma is screened out as a molecular marker through multiple bioinformatics technologies, expression of IGFBP7 in gastric adenocarcinoma is detected through immunohistochemistry, and prognosis of a patient is evaluated by establishing a scoring system combining dyeing intensity and positive cell proportion. Experimental results show that IGFBP7 knock-down can effectively inhibit proliferation and migration of gastric adenocarcinoma cells, induce apoptosis and trigger S-phase arrest. Furthermore, a co-culture experiment of gastric adenocarcinoma cells and mononuclear cells reveals that IGFBP7 can promote polarization of M2 type macrophages in a gastric adenocarcinoma tumor immune microenvironment.

The present invention relates to a method for differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF) in a subject suffering from heart failure, said method comprising the steps of determining the amounts of IGFBP7 (Insulin-like growth factor-binding protein 7), of a BNP-type peptide, and optionally of CRP (C-reactive protein) in a sample from the subject, calculating (i) a ratio of the amount of IGFBP7 and the amount of the BNP-peptide or (ii) a ratio of the sum of the amounts of IGFBP7 and CRP and the amount of the BNP-type peptide, comparing the ratio calculated with a reference ratio, and differentiating between heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF). The present invention further concerns a method for the diagnosis of HFpEF.

The application discloses application of anti-IGFBP7 antibodies in treating skin diseases, belongs to the technical field of psoriasis treatment, and discloses application of anti-IGFBP7 antibodies in preparation of a medicament for treating psoriasis, wherein the medicament is used for reducing and treating psoriasis-like inflammation by inhibiting expression of IGFBP7 in blood vessels of skin of a psoriasis patient. After the anti-IGFBP7 antibodies are used, psoriasis inflammation is reduced, meanwhile, epidermal thickness of a psoriasis patient is reduced, erythema formation is inhibited, and the generation of scales is reduced. In protecting vascular barrier function and treating psoriasis, the anti-IGFBP7 antibodies have a good medicinal prospect.